Rokni Ghasem Rahmatpour, Golpour Massoud, Gorji Alimorad Heidari, Khalilian Alireza, Ghasemi Hamta
Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran.
Education and Development Center, Mazandaran University of Medical Sciences, Sari, Iran.
J Adv Pharm Technol Res. 2017 Jan-Mar;8(1):29-33. doi: 10.4103/2231-4040.197388.
Vitiligo is one of the most primitive well-known dermatoid disorders with different suggested therapies. Therefore, this study investigated the efficiency and safety of topical tacrolimus in treatment of patients with vitiligo. This study was a clinical randomized designed study pre- post-test method, has been conducted on thirty cases with vitiligo who have referred to polyclinic and dermatology clinic. Participant's evaluated and demographic information recorded in designed checklist. In the next stage, the disease activity scored by vitiligo index disease activity system. Photography and depigmentation percent has recorded before treatment and further in 4, 8, 12, 16, 20, and 24 weeks. Finally, gathered data compared through SPSS-20 software. The final sample comprised 30 persons including: 12 men (40%) and 18 women (60%). The average of patient's age in this study was 26/13 ± 18/20 (2-76-year-old). Eleven persons was ≤15 years old and rest was older than 15. Sixty-six lesions have funded in patients that maximum has accrued on face and neck (37/87%) and trunk (21/21%). In addition, minimum of lesions is related to genitalia (9/09%). In the in 4, 8, 12, 16 weeks, improvement in face and neck had increased significantly, into the past weeks. In the 20 and 24 weeks, the improvement has increased although it was not significant enhancement. Also about trunk, in the 4 week the improvement does not have significant increasing in compare to the past week. In the eighth, 12, 16, 20, and 24 weeks the improvement has been increased significantly in compare to the past weeks. Although in the case of limbs and genitalia, the improvement was lower. There was no significant difference between male and females and age. Although the improvement was, slow in older persons. Study results, has presented applying topical tacrolimus in vitiligo, particularly in face and neck, could be effective and does not seen any specified adverse effects during consumption of tacrolimus, it could be effective in decreasing effects in use of corticosteroid.
白癜风是最常见的已知皮肤类疾病之一,有多种推荐疗法。因此,本研究调查了外用他克莫司治疗白癜风患者的有效性和安全性。本研究采用临床随机设计的前后测试方法,对30例到综合门诊和皮肤科门诊就诊的白癜风患者进行了研究。在设计好的检查表中记录参与者的评估和人口统计学信息。下一阶段,采用白癜风指数疾病活动系统对疾病活动进行评分。在治疗前以及治疗后的第4、8、12、16、20和24周记录照片和色素脱失百分比。最后,通过SPSS - 20软件对收集到的数据进行比较。最终样本包括30人,其中男性12人(40%),女性18人(60%)。本研究中患者的平均年龄为26.13±18.20岁(2至76岁)。11人年龄≤15岁,其余年龄大于15岁。患者身上共发现66处病损,其中大部分集中在面部和颈部(37/87%)以及躯干(21/21%)。此外,最少的病损与生殖器部位有关(9/09%)。在第4、8、12、16周,面部和颈部的改善情况在过去几周内显著增加。在第20和24周,改善情况有所增加,尽管增幅不显著。同样,关于躯干,在第4周与过去一周相比改善情况没有显著增加。在第8、12、16、20和24周,与过去几周相比改善情况显著增加。尽管在四肢和生殖器部位改善情况较低。男性和女性以及不同年龄之间没有显著差异。尽管老年人的改善情况较慢。研究结果表明,外用他克莫司治疗白癜风,特别是在面部和颈部,可能有效,并且在使用他克莫司期间未观察到任何特定的不良反应,它可能有助于减少皮质类固醇使用的副作用。